Here is the uncomfortable starting point. Most teams buy modular content to produce more assets, faster. Yet Veeva’s analysis of over 600 million annual HCP interactions found that nearly 80% of approved content is rarely or never used, and field teams share content in fewer than half of their customer interactions.
More variants of unused content is not a win. Done right, modular content in pharma solves a different problem: making approved, compliant content easy to find, assemble, adapt, and actually use across channels and markets.
That “done right” is what this post covers, as part of our full HCP marketing guide.
What modular content in pharma actually means
A module is a governed unit of content, not a design template. The ranking articles on this topic use module, template, fragment, and component interchangeably, and that vagueness is exactly what breaks governance later. The working definitions:
A claim is a statement about the product, tied to its evidence. A module is a reusable content unit that carries a claim or message plus everything needed to use it safely. A template is just presentation structure. An assembled asset is what a healthcare professional finally sees: an email, a detail aid, a web page built from modules.
What makes a module compliant is its metadata. A usable pharma content module carries: a unique identifier, the controlled text itself, the evidence link, product and indication, intended audience, permitted markets and channels, the label version it depends on, any mandatory risk statement that must travel with it, an owner, and approval and expiry dates.
A concrete example. An efficacy module for a cardiology brand carries the approved claim sentence, its two references, the mandatory risk line that must appear with it, the markets where the label supports it, and a June 2027 expiry tied to the label version. Drop it into an approved email and the risk line, references, and market check travel with it automatically.
If your “modules” are paragraphs in a slide library with none of that attached, you have a copy bank, not modular content. The difference decides whether reuse speeds you up or multiplies your risk.
Why modular content in pharma matters now
The evidence supports reuse and relevance, not volume. Three findings shape the honest business case.
First, content that reaches the conversation works. In the same Veeva benchmark, content-supported HCP engagements more than doubled new treatment starts and shortened the time to the next meeting by up to 25%. The bottleneck is not creation; it is getting approved content into use. The problem is not how much content pharma produces. It is how little of it gets used.
Second, channels genuinely need different assemblies. In IQVIA’s 2025 research, 73% of HCPs prefer virtual details for specific product topics and 72% find informational email more convenient than in-person visits, while 66% still value in-person interaction with reps and MSLs. One asset resized for every channel serves none of them; modules assembled per channel serve each.
Third, localization is where reuse pays twice. A module translated and locally validated once serves every asset in that market, which is the difference between adapting a campaign for three countries in weeks and rebuilding it three times.
And a word on the efficiency numbers you see in vendor material: they are real observations from their own customers, not guarantees. Platform providers report large cuts in review cycles; treat those as their figures and build your own baseline instead.
For a content production discipline this means one thing: modularity is worth it when it raises the share of approved content that gets used, per channel, per market. That is the metric the business case stands on.
The MLR reality of modular content in pharma: reuse has rules
“Approve once, use everywhere” is the myth that gets teams in trouble. A module is approved for defined contexts. The final assembled communication still has an overall impression, and that impression is what regulators judge.
Juxtaposition changes meaning. An approved efficacy module next to a weakened risk presentation creates a claim nobody approved. That is why final-context review, however streamlined, never disappears; modular done well replaces duplicate review with delta review, not with no review.
US enforcement makes the stakes concrete. Alongside the FDA’s September 2025 announcement of thousands of warning letters and roughly 100 cease-and-desist letters, the agency issued a warning letter to Eli Lilly the same day citing, among other findings, a promotional video that minimized risks and was never submitted on Form FDA 2253. The lesson for modular operations: every released execution needs final-form records and submission handling, no matter how pre-approved its parts were. This is the operational discipline a specialty pharma marketing agency has to build into the workflow itself.
In the EU, the EMA does not pre-clear medicine advertising; national authorities and codes govern it, and labels diverge by market. Reuse across countries needs country rule packs: local mandatory text, language validation, and a defined local release authority.
A module is approved for defined contexts, not forever and everywhere. Record the contexts, automate the check, and review the final assembly where it matters.
How to start with modular content in pharma: a lean team playbook
Start with the claims library, not the software. Every vendor pitch begins with a platform; every working implementation we have seen begins with content discipline that would help even without new technology.
The sequence for a lean team: One, inventory your claims and deduplicate them; most teams find the same claim phrased five ways with three different references. Two, define your module model and metadata before building anything. Three, pilot one brand and one customer journey end to end, not the whole portfolio. Four, agree assembly rules and a delta-review process with your MLR team before the first reuse, so review gets faster by design rather than by pressure. Five, measure the approved-to-activated ratio: of what MLR approves, how much reaches a healthcare professional within ninety days.
Picture the pilot after ninety days: forty claims deduplicated to twenty-two, one journey running on assembled modules, MLR reviewing deltas instead of duplicates, and a number nobody had before: how much of the approved library actually reached a healthcare professional.
The industry lens matters. Pharma teams get the most from multi-market reuse, where one module serves many label variants under country rules. Biotech teams need a lightweight version: a small, clean claims library built before launch beats an enterprise stack bought after it. Medtech teams live under intended-use boundaries, where a module that drifts past the cleared claim is a regulatory problem, not a style issue.
Where does the output go? Into the journeys that use it: marketing automation that serves the right module at the right step, and omnichannel orchestration that assembles per channel instead of copying across them.
This is how HCP Compass marketers run content engagements: modular, MLR-ready production built around a claims library, measured by what gets used rather than what gets made. Build once is the easy half. Reuse right is where the value lives.
